Reimportation Limits Remain In Medicare Agreement; HHS Study Requested
Executive Summary
HHS would conduct a study of the safety issues associated with drug reimportation under the Medicare Rx benefit 1conference agreement released Nov. 20
You may also be interested in...
Global Price Controls Cost Rx Industry $18-$27 Bil. A Year, Commerce Says
Global price controls cost pharmaceutical companies approximately $18 bil. to $27 bil. a year in lost revenue, the Commerce Department maintains in a Dec. 21 report to Congress entitled "Foreign Drug Price Controls: Their Effects on R&D, Innovation and Consumer Welfare.
Global Price Controls Cost Rx Industry $18-$27 Bil. A Year, Commerce Says
Global price controls cost pharmaceutical companies approximately $18 bil. to $27 bil. a year in lost revenue, the Commerce Department maintains in a Dec. 21 report to Congress entitled "Foreign Drug Price Controls: Their Effects on R&D, Innovation and Consumer Welfare.
FDA Rx Import Task Force Will Hold Public Hearing, Meet With Stakeholders
FDA's drug importation task force will hold a series of meetings with health care industry stakeholders and an open public hearing as it develops its report for Congress